Parabilis Medicines, Inc. - Common Stock (NQ:PBLS)

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

August 25, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Performance

52-Week Range 32.4% below 52-week high

28.71

24.5152W Low 42.4852W High

1 Week 6.8% below 1-week high

26.141W Low 30.821W High

Parabilis Medicines, Inc. - Common Stock (PBLS) traded between $24.51 and $42.48 over the past 52 weeks and last traded at $28.71, 32.4% below its 52-week high. Over the past week it ranged between $26.14 and $30.82.

Past 12 Months

-5.2%

-27.8%

-5.4%

-9.1%

1W -$1.57

1M -$11.06

3M -$1.65

6M -$2.89

YTD -$2.89

1Y -$2.89

PBLS was -9.1% over the past year, -9.1% over six months, -9.1% year to date, -5.2% in the last week.

12 Months vs Market

PBLS

-9.1%

DIA

+10.6%

SPY

+15.6%

QQQ

+22.8%

IWM

+13.1%

Over the past 12 months PBLS returned -9.1% versus DIA (Dow) +10.6%, SPY (S&P 500) +15.6%, QQQ (Nasdaq 100) +22.8% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 0.50× 3-mo avg

Today 340,521 3-mo avg 686.5K

963.9K

1.2M

686.5K

796.9K

YTD

796.9K

PBLS most recently traded 340,521 shares against a 3-month average daily volume of 686.5K.

More News

August 13, 2026

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? ↗

June 20, 2026

SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History. ↗

June 15, 2026

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗

June 12, 2026

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 11, 2026